[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20076481L - Benzimidazol-karboksamidforbindelser som 5-HT4 receptorantagonister - Google Patents

Benzimidazol-karboksamidforbindelser som 5-HT4 receptorantagonister

Info

Publication number
NO20076481L
NO20076481L NO20076481A NO20076481A NO20076481L NO 20076481 L NO20076481 L NO 20076481L NO 20076481 A NO20076481 A NO 20076481A NO 20076481 A NO20076481 A NO 20076481A NO 20076481 L NO20076481 L NO 20076481L
Authority
NO
Norway
Prior art keywords
compounds
receptor antagonists
carboxamide compounds
benzimidazole carboxamide
relates
Prior art date
Application number
NO20076481A
Other languages
English (en)
Other versions
NO339658B1 (no
Inventor
Daniel Marquess
Seok-Ki Choi
Roland Gendron
Lan Jiang
Daniel D Long
Robert M Mckinnell
Paul R Fatheree
Sean M Dalziel
Kirsten M Phizackerley
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20076481(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of NO20076481L publication Critical patent/NO20076481L/no
Publication of NO339658B1 publication Critical patent/NO339658B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår benzimidazol-karboksamid 5-HTreceptoragonistforbindelser med formel (I) hvori Rog X er som definert i beskrivelsen, eller et farmasøytisk akseptabelt salt eller solvat eller stereoisomer derav. Oppfinnelsen angår også farmasøytiske sammensetninger som innbefatter slike forbindelser, fremgangsmåter for anvendelse av slike forbindelser for behandling av sykdommer assosiert med 5-HTreceptoraktivitet og fremgangsmåter og intermediater anvendelige for fremstilling av slike forbindelser. Oppfinnelsen angår videre krystallinske former av en forbindelse med formel (I).
NO20076481A 2005-05-25 2007-12-17 Benzimidazol-karboksamidforbindelser som 5-HT4 receptoragonister NO339658B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68446605P 2005-05-25 2005-05-25
US68447805P 2005-05-25 2005-05-25
US74841505P 2005-12-08 2005-12-08
PCT/US2006/020085 WO2006127815A2 (en) 2005-05-25 2006-05-24 Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Publications (2)

Publication Number Publication Date
NO20076481L true NO20076481L (no) 2007-12-17
NO339658B1 NO339658B1 (no) 2017-01-16

Family

ID=37452788

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076481A NO339658B1 (no) 2005-05-25 2007-12-17 Benzimidazol-karboksamidforbindelser som 5-HT4 receptoragonister

Country Status (27)

Country Link
US (10) US8143279B2 (no)
EP (1) EP1899324B1 (no)
JP (2) JP5072111B2 (no)
KR (1) KR101333280B1 (no)
AR (1) AR057327A1 (no)
AT (1) ATE535523T1 (no)
AU (1) AU2006250009B2 (no)
BR (1) BRPI0611202C1 (no)
CA (1) CA2607280C (no)
CY (1) CY1112366T1 (no)
DK (1) DK1899324T3 (no)
EA (1) EA013240B1 (no)
ES (1) ES2376115T3 (no)
HK (1) HK1110980A1 (no)
HR (1) HRP20120108T2 (no)
IL (1) IL186883A (no)
MA (1) MA29541B1 (no)
MX (1) MX2007014762A (no)
MY (1) MY147756A (no)
NO (1) NO339658B1 (no)
NZ (1) NZ563068A (no)
PE (1) PE20061446A1 (no)
PL (1) PL1899324T3 (no)
PT (1) PT1899324E (no)
SI (1) SI1899324T1 (no)
TW (1) TWI388555B (no)
WO (1) WO2006127815A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1664036T3 (da) * 2003-09-03 2012-02-13 Pfizer Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7256294B2 (en) * 2005-05-25 2007-08-14 Theravance, Inc. Crystalline form of a benzimidazole-carboxamide medicinal compound
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2410857B1 (en) 2009-03-23 2014-01-29 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
PT2419104T (pt) * 2009-04-13 2018-01-31 Theravance Biopharma R&D Ip Llc Combinações de agonistas do recetor 5-ht4 e inibidores da acetilcolinesterase para o tratamento de distúrbios cognitivos
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
US9676703B2 (en) 2013-08-09 2017-06-13 Santen Pharmaceutical Co., Ltd. Production method for 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and intermediate for said production method

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
ES2109190B1 (es) 1996-03-22 1998-07-01 Univ Madrid Complutense Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht
JPH111472A (ja) 1996-04-30 1999-01-06 Dainippon Pharmaceut Co Ltd ベンズアミド誘導体及びそれを含有する医薬組成物
SK15852000A3 (sk) * 1998-04-28 2001-06-11 Dainippon Pharmaceutical Co., Ltd. Derivát 1-[(1-substituovaného-4-piperidinyl)metyl]-4-piperidínu, spôsob jeho prípravy, farmaceutický prípravok obsahujúci tento derivát a medziprodukt tohto derivátu
WO2000026192A1 (de) 1998-11-03 2000-05-11 Basf Aktiengesellschaft Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
ES2154605B1 (es) 1999-09-14 2001-11-16 Univ Madrid Complutense Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
JP2001122784A (ja) 1999-10-27 2001-05-08 Dainippon Pharmaceut Co Ltd １−［（１−置換−４−ピペリジニル）メチル］−４−ピペリジン誘導体からなる医薬
CA2410939C (en) * 2000-06-07 2010-02-16 Aryx Therapeutics Materials and methods for the treatment of gastroesophageal reflux disease
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
US7384934B2 (en) 2002-08-05 2008-06-10 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
MXPA05003065A (es) * 2002-09-20 2005-05-27 Pfizer Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4.
JP2004277318A (ja) * 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
JP2004277319A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物
JP2004277320A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １，４−ジ置換ピペリジン誘導体およびそれを含有する医薬組成物
DK1664036T3 (da) 2003-09-03 2012-02-13 Pfizer Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning
US7256294B2 (en) 2005-05-25 2007-08-14 Theravance, Inc. Crystalline form of a benzimidazole-carboxamide medicinal compound
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
HRP20120108T2 (hr) 2012-03-31
CA2607280A1 (en) 2006-11-30
SI1899324T1 (sl) 2012-03-30
US20220274957A1 (en) 2022-09-01
TWI388555B (zh) 2013-03-11
PT1899324E (pt) 2012-01-24
IL186883A0 (en) 2008-02-09
PE20061446A1 (es) 2007-01-16
JP2008542281A (ja) 2008-11-27
KR101333280B1 (ko) 2013-11-28
HRP20120108T1 (en) 2012-02-29
US20170081313A1 (en) 2017-03-23
US8377964B2 (en) 2013-02-19
WO2006127815A3 (en) 2007-08-02
EA013240B1 (ru) 2010-04-30
MA29541B1 (fr) 2008-06-02
AU2006250009A1 (en) 2006-11-30
EA200702612A1 (ru) 2008-06-30
BRPI0611202B8 (pt) 2019-09-24
US7759363B2 (en) 2010-07-20
KR20080021045A (ko) 2008-03-06
MY147756A (en) 2013-01-15
AU2006250009B2 (en) 2012-03-08
IL186883A (en) 2013-03-24
TW200716607A (en) 2007-05-01
EP1899324A2 (en) 2008-03-19
HK1110980A1 (en) 2008-07-25
US20130273568A1 (en) 2013-10-17
BRPI0611202B1 (pt) 2019-09-24
ATE535523T1 (de) 2011-12-15
ES2376115T3 (es) 2012-03-09
US9428489B2 (en) 2016-08-30
EP1899324B1 (en) 2011-11-30
NO339658B1 (no) 2017-01-16
US20150183761A1 (en) 2015-07-02
US8143279B2 (en) 2012-03-27
US20060270652A1 (en) 2006-11-30
US10696656B2 (en) 2020-06-30
US20090209582A1 (en) 2009-08-20
NZ563068A (en) 2011-01-28
DK1899324T3 (da) 2012-02-13
US11254655B2 (en) 2022-02-22
JP5072111B2 (ja) 2012-11-14
US20190152951A1 (en) 2019-05-23
JP2012197322A (ja) 2012-10-18
BRPI0611202A2 (pt) 2010-08-24
WO2006127815A2 (en) 2006-11-30
US20200283408A1 (en) 2020-09-10
US20100249186A1 (en) 2010-09-30
MX2007014762A (es) 2008-02-14
PL1899324T3 (pl) 2012-04-30
CY1112366T1 (el) 2015-12-09
US9975877B2 (en) 2018-05-22
US20180237420A1 (en) 2018-08-23
CA2607280C (en) 2013-09-17
US10233172B2 (en) 2019-03-19
AR057327A1 (es) 2007-11-28
BRPI0611202C1 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
NO20076481L (no) Benzimidazol-karboksamidforbindelser som 5-HT4 receptorantagonister
DK1856090T3 (da) Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
NO20045120L (no) Triazolderivater som takykininreseptorantagonister
NO20076498L (no) Derivater av 4-(2-amino-1-hydroksyetyl)fenol som agonister av den betta2-adrenerge reseptoren
DK1957484T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
NO20064156L (no) Indazolkarboksamidforbindelser som 5-HT4 receptoragonister
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
DK1735278T3 (da) Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser
DK1951659T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
NO20070789L (no) Nikotinreseptoragonister for behandling av betennelsessykdommer
CY1110453T1 (el) Αναστολεις υποδοχεα η3 ισταμινης, παρασκευη και θεραπευτικες χρησεις
BRPI0906632A2 (pt) Imidazolinil metil aril sulfonamidas
NO20082597L (no) Karbamatforbindelser som 5-HT4 reseptoragonister
ATE531697T1 (de) Neuartige imidazolinylmethyl-aryl-sulfonamide

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: THERAVANCE BIOPHARMA R&D IP, US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: THERAVANCE BIOPHARMA R&D IP, US

MM1K Lapsed by not paying the annual fees